Axsome Therapeutics News

Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights

Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Axsome Therapeutics (NASDAQ:AXSM) in the last three months.The table below summarizes their rec

BenzingaApr 29 10:01 ET

Axsome Therapeutics Raised to Overweight From Equal-Weight by Morgan Stanley

Axsome Therapeutics Raised to Overweight From Equal-Weight by Morgan Stanley

Dow JonesApr 29 05:36 ET

Express News | Morgan Stanley Upgrades Axsome Therapeutics to Overweight, Raises Price Target to $115

BenzingaApr 29 05:27 ET

Buy Rating Affirmed for Axsome Therapeutics on Robust Product Pipeline and Market Growth Potential

TipRanksApr 29 04:37 ET

Buy Rating Affirmed for Axsome Therapeutics Amidst Anticipated Clinical Data and Resilient Product Performance

TipRanksApr 26 02:10 ET

Neurocrine Biosciences Upgraded at Wells Fargo on Pipeline

Seeking AlphaApr 24 11:59 ET

15 Most Black States in the US

Yahoo FinanceApr 22 09:16 ET

Auvelity's Strong Performance Sustains Buy Rating for Axsome Therapeutics

TipRanksApr 16 02:56 ET

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is On The Mark

When you see that almost half of the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or "P/S") below 2.9x, Axsome Therapeutics, Inc. (NASDAQ:AXSM) looks to be giving off strong sell signals with its 12.1x P/S ratio.

Simply Wall StApr 15 08:37 ET

Express News | Axsome Therapeutics Inc - New Data for Axs-07 in Migraine Demonstrating Efficacy in Pooled Analysis

Moomoo 24/7Apr 15 07:02 ET

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

PDF Version AXS-05 in Alzheimer's disease agitation data featured in oral plenary sessionNew data for AXS-07 in migraine demonstrating efficacy in pooled analysisPresentations on cognitive and wa

Axsome TherapeuticsApr 15 00:00 ET

Express News | Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target

Moomoo 24/7Apr 10 09:35 ET

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Axsome Therapeutics (AXSM) and Premier (PINC)

TipRanksApr 10 02:21 ET

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

PDF Version NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of ce

Axsome TherapeuticsApr 10 00:00 ET

Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)

TipRanksApr 8 22:10 ET

Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 2 09:03 ET

Express News | HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Maintains $190 Price Target

Moomoo 24/7Apr 2 08:53 ET

Buy Rating Affirmed for Axsome Therapeutics Amid Strong Clinical Pipeline and Market Expansion Potential

TipRanksApr 2 06:26 ET

Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)

Yahoo FinanceApr 2 00:17 ET

Axsome Therapeutics(AXSM.US) Officer Sells US$1.9 Million in Common Stock

$Axsome Therapeutics(AXSM.US)$ Officer Jacobson Mark L. sold 24,662 shares of Common Stock on Apr 1, 2024 at an average price of $77.242 for a total value of $1.9 million.Source: Announcement What is

moomoo NewsApr 1 19:26 ET